BRIEF

on PREDILIFE (EPA:ALPRE)

Predilife reaches the milestone of 1,000 registrations for its predictive assessments

Stock price chart of PREDILIFE (EPA:ALPRE) showing fluctuations.

PREDILIFE, a specialist in predicting pathological risks, has reached a significant milestone. During Pink October, the company recorded more than 1,000 employee registrations for its predictive assessments. These assessments, launched after Covid thanks to teleconsultation, meet a strong demand: 80% of employees want to benefit from them, according to an Ipsos study.

Available for various sectors and company sizes, the assessments cover breast cancer and other major pathologies. Predilife uses proprietary medical devices to offer personalized medicine. The MammoRisk assessment, dedicated to breast cancer, benefits from an independent valuation.

High customer satisfaction and the continued expansion of balance sheets to more employees, in collaboration with insurance players, ensure promising growth for Predilife.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all PREDILIFE news